A major biotechnology firm recently caused a stir by terminating its patent agreement with the universities holding the two major patents on gene-cloning techniques and products (SN: 5/18/85, p. 312). But now Cetus Corp. of Emeryville, Calif., has reversed its position. "We are delighted that they will resume the license," says Niels Reimers of Stanford University's Office of Technology Licensing. Robert Fildes, president of Cetus, says, "We wanted to resume our license as an indication of the high regard we have for the close collaboration in many fields between our two organizations." He adds that the company's business plans have changed since the earlier action, so "... the decision also fits in with our needs going forward."
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Cetus Corp. resumes patent license with Stanford University|
|Date:||Sep 14, 1985|
|Previous Article:||New option in gene expression.|
|Next Article:||Stop the music.|